Peer-reviewed veterinary case report
Toceranib phosphate shows benefit in dogs with solid tumors
By London, C et al.·Published in Veterinary and comparative oncology·2012·Department of Veterinary Biosciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
- Species:
- dog
Plain-English summary
A group of dogs with various solid tumors, including anal sac adenocarcinoma and osteosarcoma, were treated with toceranib phosphate (Palladia) to see if it would help their condition. Out of 85 dogs, 63 showed clinical benefit, meaning their tumors either shrank or stabilized. Specifically, many dogs with anal sac adenocarcinoma had positive responses, with some experiencing partial or complete remission. The treatment was generally well-tolerated, and most dogs were on the medication for at least four months. While these results are promising, more studies are needed to confirm how effective toceranib really is for these types of cancer in dogs.
People also search for: dog cancer treatment options · toceranib phosphate for dogs · anal sac adenocarcinoma in dogs treatment
Abstract
The purpose of this study was to provide an initial assessment of the potential biologic activity of toceranib phosphate (Palladia®, Pfizer Animal Health, Madison, NJ, USA) in select solid tumours in dogs. Cases in which toceranib was used to treat dogs with apocrine gland anal sac adenocarcinoma (AGASACA), metastatic osteosarcoma (OSA), thyroid carcinoma, head and neck carcinoma and nasal carcinoma were included. Clinical benefit (CB) was observed in 63/85 (74%) dogs including 28/32 AGASACA [8 partial response (PR), 20 stable disease (SD)], 11/23 OSAs (1 PR and 10 SD), 12/15 thyroid carcinomas (4 PR and 8 SD), 7/8 head and neck carcinomas [1 complete response (CR), 5 PR and 1 SD] and 5/7 (1 CR and 4 SD) nasal carcinomas. For dogs experiencing CB, the median dose of toceranib was 2.8 mg kg(-1) , 36/63 (58.7%) were dosed on a Monday/Wednesday/Friday basis and 47/63 (74.6%) were treated 4 months or longer. Although these data provide preliminary evidence that toceranib exhibits CB in dogs with certain solid tumours, future prospective studies are necessary to define its true activity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22236194/